Skip to content
Screener

Royalty Pharma RPRX Q4 2025 Annual earnings

Reported February 11, 2026 · Before market open

Revenue$874.0MBeat by $67.0M
EPS$1.46Beat by $0.17
Revenue estimate$807.0M
EPS estimate$1.29

Next report

Nov 4, 2026 (in 2 months)
Revenue estimate$877.4M
EPS estimate$1.16

Financials

Q4 2025

Income statement

See full
Revenue$622.0M+4.8%
Operating income$388.4M+7.4%
Net income$214.2M+2.9%
EPS (diluted)$0.50+6.4%

Balance sheet

See full
Cash & equivalents$618.7M-33.4%
Total debt$9.0B+17.8%
Total equity$9.7B-6.1%
Total assets$19.6B+7.7%

Cash flow

See full
Operating cash flow$827.1M+11.4%

Valuation & ratios

Valuation

as of 12/31/25
See full
Market cap$16.51B+45.7%
Enterprise value$24.86B+38.0%
P/E21.3×+8.1×
P/S6.9×+1.9×

Profitability

See full
Operating margin65.6%+8.5pp
Net margin32.5%-5.4pp

Returns & leverage

See full
Return on equity7.7%-0.7pp
Debt / equity0.9×+0.2×
Current ratio2.4×+1.0×

FAQ

When did Royalty Pharma report Q4 2025 earnings?
Royalty Pharma (RPRX) reported Q4 2025 earnings on February 11, 2026 before market open.
What were Royalty Pharma's Q4 2025 revenue and EPS?
Royalty Pharma reported revenue of $874.0M and eps of $1.46 for Q4 2025.
Did Royalty Pharma beat estimates in Q4 2025?
Revenue beat the consensus estimate of $807.0M by $67.0M. EPS beat the consensus estimate of $1.29 by $0.17.
How did Royalty Pharma's Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 47.1% from $594.0M a year earlier and eps grew 27.0% from $1.15.
Where can I find Royalty Pharma's Q4 2025 SEC filings?
You can read the 8-K earnings release (0001802768-26-000002) and the 10-K periodic report (0001802768-26-000003) directly on SEC EDGAR. The filing index links above go to sec.gov.